Gossamer Bio
GOSS on Nasdaq. Gossamer Bio develops a drug for patients with pulmonary hypertension. Market value $5.2bn.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
Read the warning sign in its own filings
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-3.09 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 20 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$10.78 a share, 18% above its 1-year low
Over the past year the price has ranged from $9.12 to $309.60.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | n/a | $0 | $0 | $115m | $48m |
| Operating margin | |||||
| Operating margin | n/a | n/a | n/a | -52.2% | -352.2% |
| Debt to equity | |||||
| Debt to equity | 0.24 | 1.95 | 0.20 | 0.00 | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.09bn | 0.23bn | 0.23bn | 0.23bn | 0.49bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting checksSkipped: company is not yet profitable
- DebtUnknown
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 417% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $9 million last quarter, down 20% on a year ago.
- Profit: $17 million, after a loss of $38 million a year ago.
- It loses 312 cents on each $1 of sales, compared with 362 cents a year earlier.
- Over the past 12 months it spent $163 million more cash than it brought in, compared with $154 million a year earlier.
- 45% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 3 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $9m |
| December 2024 | $9m |
| March 2025 | $10m |
| June 2025 | $11m |
| September 2025 | $13m |
| December 2025 | $14m |
| March 2026 | $17m |
| June 2026 | $9m |
| Quarter to | Amount |
|---|---|
| September 2024 | -$31m |
| December 2024 | -$33m |
| March 2025 | -$37m |
| June 2025 | -$38m |
| September 2025 | -$48m |
| December 2025 | -$47m |
| March 2026 | -$47m |
| June 2026 | $17m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 17 March 2026
- Next quarterly (estimated, 10-Q)
- 12 November 2026
Who owns it
None of the long-term investors we follow own it. 170 funds in all.
Sold out this quarter
Largest holders overall
- D. E. Shaw$7mAdded
- 683 Capital Management$6mAdded
- DeepCurrents Investment Group$6mNew
- Context Capital Management$5mNew
- Worth Venture Partners$4mNew
- Kalehua Capital Management$4mAdded
- AQR Capital Management$3mAdded
- GSA Capital Partners LLP$2mAdded
- Wolverine Asset Management$2mNew
- Renaissance Technologies$2mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
8 investors own more than 5%.
- 683 Capital Management, LLCPassive investorat least 10.0%+6.1 pts(filed with 2 related holders)Since 4 June 2026
- Context Capital Management, LLCPassive investorat least 9.9%(filed with 4 related holders)Since 4 June 2026
- DeepCurrents Investment Group LLCPassive investorat least 7.7%(filed with 3 related holders)Since 4 June 2026
- D. E. Shaw & Co., L.L.C.Passive investorat least 5.1%−0.9 pts(filed with 3 related holders)Since 24 September 2026
What they said
Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following at the end of the section entitled "Voting Agreements": On July 14, 2026, shareholders approved the Shareholder Proposals (i) through (iv). Subsequently, as disclosed in the Issuer's Form 8-K…
Read the filing - Opaleye Management Inc.Passive investorat least 5.1%(filed with 2 related holders)Since 22 July 2026
- Octagon Capital Advisors LPPassive investorat least 3.8%−2.7 pts(filed with 2 related holders)Since 31 March 2026
- Invus Public Equities, L.P.Passive investorat least 2.8%(filed with 7 related holders)Since 31 December 2024
- Growth Equity Opportunities 18 VGE, LLCPassive investorat least 1.7%(filed with 11 related holders)Since 23 February 2026
What they said
On February 23, 2026, GEO completed open market sales as part of a series of public sales whereby GEO sold in the aggregate 17,093,034 shares of Common stock at a weighted average price of $0.3906 per share, with prices that ranged from $0.3320 to $0.6363 per share. GEO…
Read the filing - BlackRock, Inc.Passive investorSold down below 5%Since 30 June 2026
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
683 Capital Management, LLC Passive investor | at least 10.0%+6.1 pts (filed with 2 related holders) | 4 June 2026 | |
Context Capital Management, LLC Passive investor | at least 9.9% (filed with 4 related holders) | 4 June 2026 | |
DeepCurrents Investment Group LLC Passive investor | at least 7.7% (filed with 3 related holders) | 4 June 2026 | |
D. E. Shaw & Co., L.L.C. Passive investor | at least 5.1%−0.9 pts (filed with 3 related holders) | 24 September 2026 | What they saidItem 4 of the Schedule 13D is hereby amended and supplemented by adding the following at the end of the section entitled "Voting Agreements": On July 14, 2026, shareholders approved the Shareholder Proposals (i) through (iv). Subsequently, as disclosed in the Issuer's Form 8-K… Read the filing |
Opaleye Management Inc. Passive investor | at least 5.1% (filed with 2 related holders) | 22 July 2026 | |
Octagon Capital Advisors LP Passive investor | at least 3.8%−2.7 pts (filed with 2 related holders) | 31 March 2026 | |
Invus Public Equities, L.P. Passive investor | at least 2.8% (filed with 7 related holders) | 31 December 2024 | |
Growth Equity Opportunities 18 VGE, LLC Passive investor | at least 1.7% (filed with 11 related holders) | 23 February 2026 | What they saidOn February 23, 2026, GEO completed open market sales as part of a series of public sales whereby GEO sold in the aggregate 17,093,034 shares of Common stock at a weighted average price of $0.3906 per share, with prices that ranged from $0.3320 to $0.6363 per share. GEO… Read the filing |
BlackRock, Inc. Passive investor | Sold down below 5% | 30 June 2026 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought or sold on the open market in the last 12 months.
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Gossamer Bio’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 17 Mar 2026, plus the 10-Q filed 13 Aug 2026 and 18 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“Accordingly, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.”
Show the full paragraph
The Company’s existing cash and cash equivalents are not sufficient to fund operating plans for at least one year from the issuance date of these financial statements. Accordingly, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities, in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty.
From the 10-Q filed 13 August 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- It owes more than it owns on paper (negative equity). Often that's from borrowing to buy back shares.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.